ProAct - PBM ads

The changes to healthcare are non-stop and confusing. Each year, costs rise, regulations increase, and compliance gets more complicated. It helps to have a good partner by your side. A partner that will help you stay in check. At ProAct, we are outperforming industry trends year after year. Our flexible approach and innovative solutions help lower plan spend without sacrificing patient care. Contact us today for FREE Rx Savings Analysis and see how a proactive, employee-owned PBM can help untangle the mess. #PBM #HealthcareSavings #CostTransparency #BenefitOptimization #HealthcareCosts #EmployeeOwnership #DrugTrend

Ready to own your future? As an Accounting Supervisor in our 100% employee-owned company, you'll build real equity in the company you help grow. Apply today.

Get the latest jobs and industry news

The biggest plan cost increases are coming from therapeutic classes many plan sponsors do not expect. Understanding where spend is moving is the first step toward a stronger benefits strategy. While GLP‑1 spending growth remains strong, the rate of acceleration is moderating. This signals market maturation, not decline. Absolute spend will continue rising even as percentage growth slows. The GLP-1 pipeline will expand the market, and upcoming developments include oral GLP‑1s, higher-dose injectables, and new cardiometabolic and renal indications. High-cost innovation is driving trend upward. Fortunately, the market also includes important deflationary opportunities. The impact of exclusivity loss was $75.3 billion over the last 5 years. It will increase to $90.9 billion over the next 5 years, including significant biosimilar entries. Specifically, Humira® and Stelara® are starting to see a decrease in sales due to biosimilar alternatives with significant sales launches. However, savings are not automatic. Plans need targeted utilization management and clear provider and member communication to support adoption. While generics continue to represent the vast majority of prescription volume, the overall size of the generic market has remained relatively flat at approximately $57 billion. At the same time, branded value has become increasingly concentrated. In 2018, across the prescription industry, it took seven brand drugs to equal the total generic business; in 2025, it only took two. The upcoming prescription drug trend environment will reward preparation. Plan sponsors should review GLP-1 coverage strategy, specialty drug management, and biosimilar adoption at a minimum.

The pharmacy benefits landscape continues to evolve. Is your organization prepared for what’s ahead? ProAct’s 2026 Drug Trend Report and Drug Pipeline Report provide insights into key industry trends, new drug approvals, pipeline activity, and performance metrics to help plan sponsors make more informed decisions. Stay ahead of emerging trends and explore strategies designed to manage pharmacy benefit costs without sacrificing positive health outcomes. Download the 2026 reports today.

Chronic conditions can drive up healthcare costs — but managing them effectively can help improve outcomes and ultimately control spend. Are you prepared to invest in your members long term? ProAct's Chronic Conditions Management Solution helps plan sponsors proactively manage rising costs while improving health outcomes. Contact us today to learn how we can help you stay ahead of rising costs while delivering the care your members deserve.